Severe Asthma & Exacerbations: Dawn of a New Era?
|
|
- Polly Little
- 5 years ago
- Views:
Transcription
1 Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation, bronchial hyper-reactivity, inflammation Asthma Syndrome Phenotypes Observed characteristics Clinical presentation Trigger Response to therapy Clinical-Biologic Phenotypes Phenotype A Phenotype B Endotypes Functional or physiopathologic mechanisms (link between clinical characteristics and biological pathways) Endotype 1 Endotype 2 Endotype 3 1
2 Pharmacologic Therapy STEP 5 STEP 4 1. CHOICE CONTROLLER STEP 1 STEP 2 low-dose ICS STEP 3 low-dose ICS/LABA* Interm/high dose ICS/LABA add-on therapy e.g. Anti-IgE Anti IL-5 2. CHOICE CONTROLLER RELIEVER Consider low-dose ICS Leucotrien Receptor Antagonist (LTRA) Low-dose Theophyllin* on-demand short-acting Beta 2 -Agonist (SABA) Interm/high-dose ICS plus Tiotropium# plus low-dose ICS+LTRA High-doseICS Tiotropium# (or + Theoph*) + LTRA plus lowdose (or + Theoph*) OCS On-demand SABA or low-dose ICS/formoterol** Pavord ID et al. Lancet 2018; 391:
3 Errors with Inhalation Devices n= 4645 Updated for the CRITIKAL patients population from Price et al, Abstract presented IPCRG 2014 DPI = dry powder inhaler; MDI = metered-dose inhaler LAMA worth a try Israel E, Reddel HK. N Engl J Med 2017;377:
4 Refractory Asthma Incomplete control with GINA Step 4/5 Loss of control when reducing therapy intensity No Is it Asthma? Yes Differential ACO Bronchiectases EGPA ABPA CF EAA VCD Neoplasia No Severe Asthma Complicating Factors? Yes Difficult-to-control Asthma Adapted from Chung KF. Eur Respir J : Risk factors for exacerbations include: Uncontrolled asthma symptoms Additional risk factors, even if the patient has few symptoms: High SABA use ( 3 canisters/year) Having 1 exacerbation in last 12 months Low FEV 1 ; higher bronchodilator reversibility Incorrect inhaler technique and/or poor adherence Smoking Obesity, chronic rhinosinusitis, pregnancy, blood eosinophilia Elevated FeNOin adults with allergic asthma taking ICS Ever intubated for asthma Risk factors for fixed airflow limitation include: No ICS treatment, smoking, occupational exposure, mucus hypersecretion, blood eosinophilia; pre-term birth, low birth weight Risk factors for medication side-effects include: Frequent oral steroids, high dose/potent ICS, P450 inhibitors 4
5 Severe Asthma: Biologics for Anti-IgE Omalizumab Anti-IL5 Mepolizumab Reslizumab Benralizumab Anti-IL4/IL13 Dupilumab Anti-TSLP Tezepelumab Brusselle G Nat Med
6 Brusselle G Nat Med 2013 Omalizumab: Exacerbations Severe exacerbation rate week 28 * Omalizumab (n=209) p= Placebo (n=210) *Severe exacerbation defined as reduction in PEF or FEV 1 to <60% of personal best and requiring treatment with systemic corticosteroids Humbert M et al., Allergy, 2005, Mar;60(3):
7 Brusselle G Nat Med 2013 Mepolizumab (Anti-IL5) Severe eosinophilic asthma: -frequent exacebations >3.5/yr -ICS > 880 mcg FP -25% OCS -blood eosinophilia > 0.28 G/L -FEV1 <65% Duration 28 weeks Mepo 75mg iv. u. 100mg/Monat sc Annual exacerbation rate: Placebo (n=191): Mepo 75mg iv (n=191): ** Mepo 100mg sc (n=194): ** FEV1: Δ + 146ml (iv), + 136ml (sc) ** AQLQ: Δ 0.42 (iv), 0.44 (sc) ** Ortega HG. N Engl J Med 2014;371:
8 Mepolizumab (Anti-IL5) Severe asthma treated with OCS: -frequent exacerbations >2.9/yr -ICS > 880 mcg FP - Median OCS Dose >12mg/d -Blood eosinophilia > 0.23 G/L -FEV1 <60% Duration 20 wks Mepo 100mg/month sc median OCS Dose: 0% PL, -50% Mepo Annual exacerbation rate: Placebo (n=66): Mepo 100mg sc (n=69): * FEV1: Δ + 128ml NS ACQ-5: Δ 0.52 ** Bel EH. N Engl J Med 2014;371: Clinical practice: optimisation period Clinical trials: control group Clinical Improvement Specific treatment Placebo effect Hawthorne effect Natural history Time 8
9 WINDWARD Program in Asthma: Benralizumab Phase 3 Clinical Trials CALIMA 2 Efficacy and safety study of benralizumab in adults and adolescents with asthma, inadequately controlled on mediumto high-dosage ICS-LABA ZONDA 6 Efficacy and safety study of benralizumab to reduce OCS use in patients with uncontrolled asthma on highdosage ICS-LABA and chronic OCS therapy SIROCCO 4 Efficacy and safety study of benralizumab added to high-dosage ICS-LABA in patients with uncontrolled asthma BORA 7 Safety extension study of benralizumab in asthmatic adults and adolescents on ICS-LABA BISE 5 Efficacy and safety study of benralizumab in adults with mild to moderate persistent asthma Six Phase 3 trials in 3068 patients and 798 sites, across 26 countries 1 GREGALE 3 Functionality and reliability of the APFS in an at-home setting and performance of the APFS after use 1. AstraZeneca press release. Published May 17, FitzGerald JM et al. Lancet. 2016; 3. Study NCT ClinicalTrials.gov website 4. Bleecker ER et al. Lancet Ferguson GT et al. Lancet Respir Med Nair P et al. N Engl J Med Study NCT ClinicalTrials.gov website. Benralizumab: Cumulative Exacerbations SIROCCO (48 weeks) 1 CALIMA a (56 weeks) 2 1. Bleecker ER et al. Lancet. 2016; 2. FitzGerald JM et al. Lancet
10 Benralizumab: Summary SIROCCO/CALIMA CALIMA Exacerbations FEV1 Q4W s.c. Q8W s.c. Q4W s.c. Q8W s.c. Eos > 300/μl -36% -28% +125mL +116mL Eos < 300/μl -30% -40% ns ns SIROCCO Eos > 300/μl -45% -51% +106mL +159mL Eos < 300/μl -30% -17% ns ns 1. Bleecker ER et al. Lancet. 2016; 2. FitzGerald JM et al. Lancet Benralizumab: OCS sparing (ZONDA) Prednisolone Change Exacerbations Nair P et al. N Engl J Med 2017;376:
11 Brusselle G Nat Med 2013 Lebrikizumab (Anti-IL-13): LAVOLTA I & II Hanania NA et al. Lancet Respir Med Oct;4(10):
12 Lebrikizumab (Anti-IL-13): LAVOLTA I & II Hanania NA et al. Lancet Respir Med Oct;4(10): Brusselle G Nat Med
13 Dupilumab (Anti-IL4R): Exacerbations Exacerbations Q4W 200mg Q4W 300mg Q2W 200mg Q2W 300mg All -54% -33% -70% -71% Eos > 300/μl -66% -35% -71% -81% Eos < 300/μl -43% -37% -68% -60% Wenzel SE et al. Lancet Jul 2;388(10039): Brusselle G Nat Med
14 Tezepelumab (Anti-TSLP) Corren J et al. N Engl J Med 2017;377: Tezepelumab (Anti-TSLP) IgE >100 IU/ml blood Eos >0.14G/L Corren J et al. N Engl J Med 2017;377:
15 Anti-IgE versus Anti-IL5? Anti-IgE? Anti-IL5 Total IgE Eosinophils Asthma Phenotype early onset late onset Adapted from Lommatzsch M Deutche Med Wochenschrift 2016 Choosing the right Biologic: Role of Co-Morbidities Anti-IgE Omalizumab Chronic rhinosinusitis with nasal polyposis Allergies Urticaria ABPA Maurer M. NEJM 2013 Voskamp AL. JACI 2015 Anti-IL5 Mepolizumab Reslizumab Benralizumab Chronic rhinosinusitis with nasal polyposis Hypereosinophilia EGPA (Churg-Strauss) Roufosse F. JACI 2013 Kim S. JACI 2010 Wechsler ME. NEJM 2017 Anti-IL4/IL13 Dupilumab Chronic rhinosinusitis with nasal polyposis Atopic dermatitis Simpson EL. NEJM 2016 Blauvelt A. Lancet
16 T2 versus non-t2 Asthma T2 nt2 nt2 Haldar P. N Engl J Med Mar 5;360(10): Israel E, Reddel HK. N Engl J Med 2017;377:
17 Dysbiosis & Neutrophilic Asthma Taylor SL. J Allergy Clin Immunol 2018;141: Obesity & Neutrophilic Asthma Scott HA et al. Allergy 2016; 71:
18 Azithromycin & Neutrophilic Asthma Gibson PG. Lancet 2017; 390: T2 versus non-t2 Asthma T2 Asthma ICS, OCS Non-T2 Asthma OCS high dose ICS altered airway microbiota systemic inflammation oxidative stress Paucigranulocytic Asthma usually mild asthma severe asthma associated with excessive use of SABA Neutrophilic Asthma usually mild-moderate asthma severe asthma + frequent exacerbations possible Anti-IL17 (Brodalumab) Anti-CXCR2 (AZD 5069) + Azithromycin 18
19 Phenotype-directed Asthma Therapy Inflammation Allergic Eosinophilic Non-allergic Neutrophilic Pauci -granulocytic Fixed Obstruction Hyperplasia bronchial smooth muscle High-dose ICS Nasal ICS LTRA OCS + Azithromycin Weight loss female obese asthma + Bronchial Thermoplasty? Biologics Immunotherapy Adapted from Rothe T et al. Schweiz Med Forum 2015 Time to review asthma therapy concept? Reliever e.g. SABA, SAMA Controller e.g. ICS, LTRA Collateral efficacy e.g. Biologic & nasal polyps Disease modifier e.g. Biologic, AIT Bateman E ERS
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationSEVERE ASTHMA - EVIDENCE TABLES APPENDIX 1
Section 2: Biomarkers Biomarkers to predict response to biologic therapies and macrolides Summary of randomized controlled trials Cut-offs Cut-off selection Study Design N Drug Predictive ability to identify
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationProf Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationNew TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator
New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate
More informationTreatment of Severe Asthma: Biologics to Bronchial Thermoplasty. Disclosures
Treatment of Severe Asthma: Biologics to Bronchial Thermoplasty Monica Kraft, M.D. Robert and Irene Flinn Professor of Medicine Chair, Department of Medicine Deputy Director, Asthma and Airway Disease
More informationJamie Lee Memorial Lecture ( ) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab
Jamie Lee Memorial Lecture (1958-2017) Targets and Outcomes: Mepolizumab, Benralizumab, Reslizumab Larry Borish, M.D. Professor of Medicine and Microbiology University of Virginia Conflict of Interest
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationSubject: Fasenra (benralizumab) Original Effective Date: 7/10/2018. Policy Number: MCP-319. Revision Date(s):
Subject: Fasenra (benralizumab) Original Effective Date: 7/10/2018 Policy Number: MCP-319 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is
More informationPFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2015?
Global Initiative for Asthma (GINA) What s new in GINA 2015? GINA Global Strategy for Asthma Management and Prevention What s new in GINA 2015 (1) Add-on tiotropium by soft-mist inhaler is a new other
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationBrooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C
Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C Associate Professor of Pharmacy Practice Southwestern Oklahoma State University College of Pharmacy Oklahoma Society of Health System Pharmacists Annual Meeting
More informationAddressing Unmet Medical Needs in Severe Asthma: Where Do We Stand?
Addressing Unmet Medical Needs in Severe Asthma: Where Do We Stand? An Expert Consensus Presented by: Michael Blaiss, MD, FACAAI Mario Castro, MD, MPH Provided by the American College of Allergy, Asthma
More informationNew Therapies for Asthma
New Therapies for Asthma Tracy Bridges, MD Speaker Disclosure: Dr. Bridges participates in speaker bureaus for Teva, Genetech & Astra Zeneca. Objectives: Discuss the use of LAMA s for Asthma Detail the
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationCHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board
CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CONFLICT OF INTEREST Employee of Auckland District Health
More informationChanging Epidemiology: Quick Facts 9/28/2018. During the year New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits? Conflict of Interest Statement 2018 Speakers Bureau Astra Zeneca Boehringer Ingelheim Genentech Sunovion Ron Balkissoon MD DIH
More informationManagement of Severe Asthma Including Biologics and Bronchial Thermoplasty. Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC
Management of Severe Asthma Including Biologics and Bronchial Thermoplasty Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC Disclosures ALK speaker Monaghan Medical Corporation speaker Novartis speaker
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationEFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Severity Assessment, Guidelines, and New Therapeutic Options
Educational Objectives EFFECTIVE ASTHMA MANAGEMENT IN PRIMARY CARE Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP President-Elect, American College of Allergy, Asthma & Immunology Medical Director,
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationImmunomodulators: Anti-IgE mab. Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE
Immunomodulators: Anti-IgE mab Thomas B. Casale, MD Professor of Medicine Chief, Allergy/Immunology Creighton University Omaha, NE Objectives To explain the rationale behind IgE blockade To discuss which
More informationUpdate on Biologicals for ABPA and Asthma
Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationThe Pharmacist s Role in Managing Severe Asthma. This activity is supported by an educational grant from Genentech. Educational Objectives
The Pharmacist s Role in Managing Severe Asthma Jennifer M. Malinowski, PharmD, RPh Assistant Dean, Academic Affairs Associate Professor, Pharmacy Practice Wilkes University School of Pharmacy Wilkes-Barre,
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationGeneral Comments to the Author: Reviewer #1 Well done!!
REVIEWERS COMMENTS General Comments to the Author: Reviewer #1 Well done!! Reviewer #2 The strengths of this guideline on severe asthma are first, that the set-up is modular with questions that are relevant
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationLINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More information7/7/2015. Somboon Chansakulporn, MD. History of variable respiratory symptoms. 1. Documented excessive variability in PFT ( 1 test)
Definition of Asthma GINA 2010: Chronic inflammatory disorder of the airways Airway hyper-responsiveness Recurrent wheezing, breathlessness, chest tightness, coughing Variable, reversible airflow obstruction
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationABCs of Immune Modifiers. Relevant Disclosures
ABCs of Immune Modifiers Dennis K. Ledford, MD Ellsworth and Simmons Professor of Allergy/Immunology University of South Florida Morsani College of Medicine Tampa, FL USA Relevant Disclosures Research
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationPotential new targets for drug development in severe asthma
Zhu et al. World Allergy Organization Journal (2018) 11:30 https://doi.org/10.1186/s40413-018-0208-1 REVIEW Potential new targets for drug development in severe asthma Linda Zhu 1,2, Christina E. Ciaccio
More informationStep up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationPrecision Asthma Therapy: Picking the Right Biologic for the Right Patient. The Asthma Umbrella. Asthma. Late onset. Early onset.
recision Asthma Therapy: icking the Right Biologic for the Right atient The Asthma Umbrella Asthma arly onset Late onset Symptoms xacerbations FV1 T H 2 inflammation No or less T H 2 inflammation henotype
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationAsthma Update Eric S. Papierniak, DO Malcom Randall VAMC Assistant Professor of Medicine UF Div. of Pulmonary, Critical Care, and Sleep Medicine
Asthma Update 2014 Eric S. Papierniak, DO Malcom Randall VAMC Assistant Professor of Medicine UF Div. of Pulmonary, Critical Care, and Sleep Medicine Goals/Objectives Review of 2014 GINA guidelines Significant
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Asthma Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Injectable Asthma Agents Xolair (omalizumab) Prime Therapeutics will
More informationCOPD and Asthma Update. April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute
COPD and Asthma Update April 29 th, 2017 Rachel M Taliercio, DO Staff, Respiratory Institute What we ll be talking about COPD: diagnosis, management of stable COPD, COPD exacerbations Asthma: diagnosis,
More informationPOCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION
POCKET GUIDE FOR ASTHMA MANAGEMENT AND PREVENTION (for Adults and Children Older than 5 Years) A Pocket Guide for Health Professionals Updated 2018 BASED ON THE GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND
More informationPrecision medicine in asthma: linking phenotypes to targeted treatments
REVIEW C URRENT OPINION Precision medicine in asthma: linking phenotypes to targeted treatments Kian F. Chung a,b Purpose of review Asthma is a heterogeneous disease consisting of different phenotypes
More informationDrug Prior Authorization Guideline NUCALA (mepolizumab)
Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and
More informationEmerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More information5/1/18. Emerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationPolicy Effective 4/1/2018
Corporate Medical Policy Interleukin-5 Antagonists Notification File Name: Origination: Last CAP Review: Next CAP Review: Last Review: interleukin_5_antagonists 2/2016 11/2017 11/2018 2/2018 Policy Effective
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationRESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA )
UnitedHealthcare Community Plan Medical Benefit Drug Policy RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) Policy Number: CS2018D0055D Effective Date: May 1, 2018 Table of Contents Page INSTRUCTIONS
More informationWhat s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals
What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals Asthma is an inflammatory disease Relaxed smooth muscles Air trapped in alveoli Tightened
More informationRising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
More informationWEBINAR. Difficult-to-treat and severe asthma: changing the paradigm
WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationDelivering in Respiratory ATS Analyst Briefing
Delivering in Respiratory ATS Analyst Briefing James Ward-Lilley, VP of RIA Therapy Area AstraZeneca Bing Yao, SVP & Head RIA imed MedImmune 20 May 2014 San Diego Cautionary statement regarding forward-looking
More informationAsthma Treatment Update: 2018
Asthma Treatment Update: 2018 John B. Cox MD Clinical Professor Division of Pulmonary, Critical Care, Allergy and Sleep Medicine Medical University of South Carolina Disclosures I have no conflicts and
More informationand one and and not any and and and
RESPIRATORY INTERLEUKINS (CINQAIR, FASENRA, AND NUCALA ) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2019D0055G Effective Date: March 1, 2019 Instructions for Use Table of Contents
More informationSymptoms are worse at night and in the morning and includes cough, whz, chest tightness.
Asthma Review ETIOLOGY Airflow limitation is caused by the following: - bronchoconstriction - mucous pluggin - airway inflammation Sudden death - heavy mucous plugging is common - typically occurs between
More informationStudy Investigators/Centers: GSK sponsored studies MEA112997, MEA115588, and MEA and a proof of concept investigator sponsored study CRT110184
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationSingle Technology Appraisal (STA) Benralizumab for treating severe asthma
Single Technology Appraisal (STA) Benralizumab for treating severe asthma Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments received
More informationEmerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More information10/24/2016. Precision Management of Severe Asthma How, When and Where. The Goals of Today s Presentation
1/24/216 Precision Management of Severe Asthma How, When and Where. Reynold A. Panettieri, Jr., MD Vice Chancellor for Clinical & Translational Science Director, Rutgers Institute for Translational and
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationVerso una terapia personalizzata delle malattie ostruttive
Verso una terapia personalizzata delle malattie ostruttive Fabio Ricciardolo Dipartimento di Scienze Cliniche e Biologiche Malattie dell Apparato Respiratorio Università di Torino COI Rapporti di natura
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationSevere eosinophilic asthma: a roadmap to consensus
EDITORIAL EOSINOPHILIC ASTHMA Severe eosinophilic asthma: a roadmap to consensus Roland Buhl 1, Marc Humbert 2, Leif Bjermer 3, Pascal Chanez 4, Liam G. Heaney 5, Ian Pavord 6, Santiago Quirce 7, Johann
More informationOmalizumab (Xolair) NHLBI normal ranges by age for FEV 1/FVC 8-19 years of age 85%; years of age 80%;
DRAFT Medical Coverage Policy Injectable Agents for Asthma and Chronic Idiopathic Urticaria Fasenra, Nucala, Xolair, Cinqair EFFECTIVE DATE: 03 01 2018 POLICY LAST UPDATED: 03 20 2018 OVERVIEW This policy
More informationManaging severe asthma in adults: lessons from the ERS/ATS guidelines
REVIEW C URRENT OPINION Managing severe asthma in adults: lessons from the ERS/ATS guidelines Kian Fan Chung a,b Purpose of review To review the latest guidelines on severe asthma. Recent findings An updated
More informationDiagnosis and Management of Fungal Allergy Monday, 9-139
Diagnosis and Management of Fungal Allergy Monday, 9-139 13-2010 Alan P. Knutsen,, MD Director, Pediatric Allergy & Immunology Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More information